Daprodustat: First Approval.

Article Details

Citation Copy to clipboard

Dhillon S

Daprodustat: First Approval.

Drugs. 2020 Sep;80(14):1491-1497. doi: 10.1007/s40265-020-01384-y.

PubMed ID

32880805 [ View in PubMed

]

Abstract

Daprodustat (DUVROQ) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (PHD) developed by GlaxoSmithKline for the treatment of anaemia in patients with chronic kidney disease (CKD). Inhibition of PHD prevents degradation of hypoxia-inducible factor (HIF), leading to the production of erythropoietin and subsequent induction of erythropoiesis. In June, daprodustat received its first approval in Japan for the treatment of renal anaemia. Clinical studies of daprodustat are underway in multiple countries worldwide. This article summarizes the milestones in the development of daprodustat leading to this first approval for the treatment of renal anaemia.

DrugBank Data that Cites this Article

Drugs

Daprodustat

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Daprodustat	Egl nine homolog 1	Protein	Humans	Yes	Inhibitor	Details
Daprodustat	Egl nine homolog 2	Protein	Humans	Yes	Inhibitor	Details
Daprodustat	Egl nine homolog 3	Protein	Humans	Yes	Inhibitor	Details

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software
Daprodustat Ritonavir	The metabolism of Daprodustat can be decreased when combined with Ritonavir.
Daprodustat Erlotinib	The metabolism of Daprodustat can be decreased when combined with Erlotinib.
Daprodustat Fluticasone propionate	The metabolism of Daprodustat can be decreased when combined with Fluticasone propionate.
Daprodustat Clopidogrel	The metabolism of Daprodustat can be decreased when combined with Clopidogrel.
Daprodustat Candesartan cilexetil	The metabolism of Daprodustat can be decreased when combined with Candesartan cilexetil.